Skip to content
Research/Peptides/CJC-1295 (with DAC)

CJC-1295 (with DAC)

Mod GRF 1-29 with Drug Affinity Complex. Long-acting synthetic GHRH analog with Drug Affinity Complex modification. Creates high, sustained GH release. Half-life ~8 days. Used for sustained GH elevation.

Intelligence Profile

Science

Mechanism of Action

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the body's natural growth hormone production. However, the available evidence on its specific molecular mechanisms is extremely limited.

Based on the single retrieved study from Frontiers in Endocrinology (2026), CJC-1295 with DAC appears to work by modulating the growth hormone-insulin-like growth factor 1 (GH-IGF1) axis. This suggests the compound likely:

  • Binds to GHRH receptors in the anterior pituitary gland
  • Stimulates the release of endogenous growth hormone
  • Subsequently increases IGF-1 production, primarily in the liver
  • Extends the half-life of the peptide through the DAC modification, potentially allowing for less frequent dosing

The DAC component is theoretically designed to bind to albumin in the bloodstream, which would prolong the peptide's activity compared to natural GHRH or unmodified synthetic analogs.

Evidence limitations: The current evidence base is severely limited, with only one review article available and no clinical trials retrieved. The molecular mechanisms described above are largely theoretical based on the compound's structural design rather than proven through rigorous clinical studies. More research is needed to establish the precise pharmacokinetics, receptor binding affinity, and downstream effects of CJC-1295 with DAC.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.